HONG KONG – Takeda Pharmaceutical Co. Ltd. has signed a $100 million deal with Portal Instruments Inc. to develop and commercialize a needle-free drug delivery system.
HONG KONG – Takeda Pharmaceutical Co. Ltd. has signed a $100 million deal with Portal Instruments Inc. to develop and commercialize a needle-free drug delivery system.
HONG KONG – Samsung Bioepis Co. Ltd. has received approval in both South Korea and Europe for its Herceptin biosimilar. Known as Samfenet in South Korea and as Ontruzant in Europe, it marks the first Herceptin biosimilar to be approved by the European Commission.
HONG KONG – Kunshan Riboquark Pharmaceutical Technology Co. Ltd. enrolled the first patient in China for its global pivotal phase II/III study of ocular neuroprotectant candidate QPI-1007.
HONG KONG – Kunshan Riboquark Pharmaceutical Technology Co. Ltd. enrolled the first patient in China for its global pivotal phase II/III study of ocular neuroprotectant candidate QPI-1007.
